Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup carbapenem.

Meropenem was developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem.

Unlike imipenem, it is stable to renal dehydrogenase and can therefore be given without cilastatin. In penetrates into the cerebrospinal fluid.